EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma

Carina Dumo, Faheem iD, Peter J Choi, Nicholas J Pederson, Yuge Liu, Mike Dragunow, Thomas I-H Park, Katharine L Diehl, Jiney Jose iD

ChemMedChem · 28.04.2026 · 21 (8)

DOI: 10.1002/cmdc.70286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 25.04.2026. Verfasst von Carina Dumo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Phthalazines, Piperazines, Poly(ADP-ribose) Polymerase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, Cure Kids.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibition of DNA damage repair is a common mechanism to induce cancer cell death and, therefore, to treat cancers such as breast, prostate and ovarian cancer. This approach, although very attractive, has not been feasible for treating brain tumours due to the stringent structural features necessary for pharmaceutical agents to cross the blood–brain barrier (BBB). This study presents the proof of concept in vitro cellular activity of PARP1 (Poly(ADP‐ribose) polymerase 1) enzyme inhibitor olaparib conjugated with a known BBB‐crossing heptamethine cyanine dye. We also present evidence for cellular uptake and PARP1 inhibition by the conjugate, which contributes to the observed improvement in potency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsCarbocyaninesGlioblastomaHumansPoly (ADP-Ribose) Polymerase-1Structure-Activity RelationshipCell Line, TumorPoly(ADP-ribose) PolymerasesDrug Screening Assays, AntitumorMolecular StructureDose-Response Relationship, DrugBrain Neoplasms

Stichwörter der Autor:innen

PARP inhibitionglioblastomaheptamethine cyanine dyesolaparib

Substanzen

olaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsPoly (ADP-Ribose) Polymerase-1Antineoplastic AgentsCarbocyaninesPARP1 protein, humanPoly(ADP-ribose) Polymerases

Autor:innen und Institutionen

  • Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland, New Zealand.
  • Department of Pharmacology & The Centre for Brain Research, University of Auckland, Auckland, New Zealand.
  • Neurosurgical Research Unit, The Centre for Brain Research, University of Auckland, Auckland, New Zealand.
  • Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.
  • Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah, USA.

ORCID-Profile: Faheem, Jiney Jose

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • Cure Kids
  • Neurological Foundation of New Zealand
  • Child Health Research Foundation
  • US National Institutes of Health

Zitieren

APA

Dumo, C., Faheem, Choi, P. J., Pederson, N. J., Liu, Y., Dragunow, M., Park, T. I., Diehl, K. L., & Jose, J. (2026). In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma. ChemMedChem, 21(8). https://doi.org/10.1002/cmdc.70286

Vancouver

Dumo C, Faheem, Choi PJ, Pederson NJ, Liu Y, Dragunow M, et al. In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma. ChemMedChem. 2026;21(8). doi:10.1002/cmdc.70286

BibTeX
@article{Dumo2026,
  author = {Dumo, Carina and Faheem and Choi, Peter J and Pederson, Nicholas J and Liu, Yuge and Dragunow, Mike and Park, Thomas I-H and Diehl, Katharine L and Jose, Jiney},
  title = {In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {8},
  doi = {10.1002/cmdc.70286}
}
Kostenlos starten →